At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Escalation Open Label Trial to Assess Safety and Immunogenicity of Candidate ChAdOx1- and MVA- Vectored Conserved Mosaic HIV-1 Vaccines Given Sequentially to Healthy HIV-1 Negative Adult Volunteers in Oxford, UK
In Brief
A Phase 1 clinical trial evaluating ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), and 1 other intervention for HIV. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers. In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.tHIVconsv1, MV.tHIVconsv3 and MVA.tHIVconsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers. 3 healthy, HIV-1 negative adult volunteers will receive one vaccination of low dose ChAdOx1.tHIVconsv1. A further 10 healthy, HIV-1 negative adult volunteers will receive a higher dose of ChAdOx1.tHIVconsv1, followed by one vaccination each of MVA.tHIVconsv3 and MVA.tHIVconsv4 4 weeks later.
Study Details
Timeline
Interventions
ChAdOx1.tHIVconsv1 5 x 10\^9 vp
ChAdOx1.tHIVconsv1 5 x 10\^10 vp
MVA.tHIVconsv3 1 x 10\^8 pfu
MVA.tHIVconsv4 09. x 10\^8 pfu